<DOC>
	<DOCNO>NCT00621140</DOCNO>
	<brief_summary>To investigate efficacy , safety tolerability BI 1356 versus placebo</brief_summary>
	<brief_title>Efficacy Safety BI 1356 ( Linagliptin ) Versus Placebo Type 2 Diabetic Patients With Insufficient Glycemic Control</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : Male female patient type 2 diabetes insufficient glycaemic control . Age 18 old 80 year Exclusion criterion : Use one oral antidiabetic agent within 10 week prior inform consent , insulin , glitazones GLP1 analogue within 3 month . Myocardial infarction , stroke transient ischaemic attack within 6 month prior inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>